( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

24 May, 2017, 16:07 ET Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on JZP-110 and Xyrem®...


24 May, 2017, 16:05 ET Jazz Pharmaceuticals to Present Phase 3 Data on JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy and with Obstructive Sleep Apnea, During 31st Annual SLEEP Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that twelve abstracts supporting the company's sleep medicine portfolio, including...


16 May, 2017, 16:05 ET Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


09 May, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results

Total Revenues Increased 12% to $376 Million Settled Xyrem Patent Litigation with First ANDA Filer Completed Rolling NDA Submission for Vyxeos...


26 Apr, 2017, 16:05 ET Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from the global multicenter study of JZP-110 in adult patients...


25 Apr, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2017 first quarter financial results on Tuesday, May 9, 2017, after...


05 Apr, 2017, 16:30 ET Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that certain of its subsidiaries have entered into agreements with Hikma Pharmaceuticals...


03 Apr, 2017, 09:05 ET Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion on March 31, 2017 of a rolling submission of a New Drug Application (NDA) to...


30 Mar, 2017, 02:00 ET Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into license agreements with Nippon Shinyaku, Co., Ltd. for Defitelio®...


20 Mar, 2017, 09:00 ET Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy results from two global multicenter studies in adult patients with...


15 Mar, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an...


01 Mar, 2017, 16:05 ET Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


28 Feb, 2017, 16:05 ET Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2016 and provided financial...


14 Feb, 2017, 16:05 ET Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 fourth quarter and full year financial results on Tuesday,...


08 Feb, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a...


17 Jan, 2017, 16:02 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial comparing the...


03 Jan, 2017, 16:05 ET Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 9

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 35th Annual J.P....


28 Nov, 2016, 16:05 ET Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in...


10 Nov, 2016, 16:05 ET Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


08 Nov, 2016, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2016 and updated financial guidance for...


07 Nov, 2016, 16:05 ET Jazz Pharmaceuticals to Present New Data at the Annual ASH Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that eleven abstracts, including four oral presentations, supporting the company's...


25 Oct, 2016, 16:05 ET Jazz Pharmaceuticals to Report 2016 Third Quarter Financial Results on November 8, 2016

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2016 third quarter financial results on Tuesday, November 8, 2016,...


03 Oct, 2016, 08:30 ET Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017

Jazz Pharmaceuticals plc (Nasdaq; JAZZ) today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States...


26 Sep, 2016, 16:05 ET Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea

 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that patient enrollment has been completed for its two Phase 3 studies evaluating...


07 Sep, 2016, 16:05 ET Jazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Morgan Stanley...